|
**Overview**: Enhanced Liver Fibrosis Panel**Introduction**: The Enhanced Liver Fibrosis Panel is a diagnostic tool designed to assess liver fibrosis using serum samples. In India, chronic liver disease (CLD) affects millions (prevalence ~4-5 percent for NAFLD, higher for viral hepatitis), with fibrosis progression leading to cirrhosis and hepatocellular carcinoma. ELF score (combining hyaluronic acid, PIIINP, TIMP-1) is a validated noninvasive marker for advanced fibrosis, superior to single markers in NAFLD, hepatitis B/C, and alcoholic liver disease. High morbidity from underdiagnosis in rural/low-SES patients, limited elastography access, delayed antifibrotic/lifestyle intervention leading to decompensation. Per hepatology practices aligned with ICMR and Indian National Association for Study of the Liver guidelines, the test employs spectrophotometry for biomarkers and ELF score calculation over 1-2 days with high accuracy, valuable for risk stratification without biopsy. This diagnostic falls under liver disease screening and targets patients with elevated ALT, NAFLD risk, or chronic hepatitis, addressing accurate fibrosis detection to guide monitoring or referral. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise noninvasive assessment and reducing cirrhosis burden. Its serum-based approach ensures reliable performance in India's diverse laboratory settings.**Other Names**: ELF Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.**Historical Milestone**: ELF score validated; in India, adopted in NAFLD/hepatitis clinics.**Purpose**: The test assesses 4 parameters including hyaluronic acid to calculate ELF score, guide liver fibrosis evaluation, stratify risk, inform management.**Test Parameters**: 1. Hyaluronic Acid, 2. PIIINP, 3. TIMP-1, 4. ELF Score.**Pretest Condition**: Fasting 10-12 hours recommended; patients should report fatigue, jaundice, or risk factors.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on alcohol use, viral hepatitis, obesity, diabetes.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated fibrosis including cirrhosis, benefits of noninvasive assessment, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique, avoid hemolysis, and calculate ELF score within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or inflammation can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: High ELF score indicates advanced fibrosis, necessitating specialist input. Low score may require follow-up in high-risk.**Specialist Consultation**: Hepatologists should be consulted for management.**Additional Supporting Tests**: FibroScan, liver biopsy for confirmation.**Test Limitations**: Less accurate in acute hepatitis; comprehensive approach required.**References**: Indian Journal of Gastroenterology 2024, Liver Fibrosis Studies India 2023. |
